FMR1 and fragile X syndrome: Currently, the only pharmacologic agent that substantially reactivates FMR1 in FXS is 5-aza-dC, a cytosine analog that non-selectively induces gene expression by interfering with the pathways that lead to epigenetic gene silencing [7].